瑞普生物(300119) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 reached ¥568,423,568.34, an increase of 24.05% year-over-year[7] - Net profit attributable to shareholders was ¥93,188,240.25, up 5.17% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥80,725,500.19, a 5.49% increase year-over-year[7] - The company's operating revenue for the period was approximately 1.48 billion CNY, a slight decrease from 1.50 billion CNY in the previous period[40] - The net profit for the current period is ¥256,016,202.77, a decrease of 20% compared to ¥319,799,858.54 in the previous period[45] - The total operating income for the current period is ¥1,375,885,824.91, down from ¥1,472,348,697.81 in the previous period[49] - The operating profit is ¥284,666,735.22, compared to ¥360,731,153.64 in the previous period, reflecting a decline of approximately 21%[49] - The basic earnings per share for the current period is ¥0.5036, down from ¥0.7358 in the previous period[45] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥6,178,265,581.62, reflecting an 8.57% increase from the end of the previous year[7] - The company's total liabilities as of September 30, 2022, were approximately 1.79 billion CNY, compared to 1.37 billion CNY at the beginning of the year[38] - The company's current assets totaled approximately 3.18 billion CNY, up from 3.06 billion CNY at the beginning of the year[32] - The company's long-term equity investments increased to approximately 375.31 million CNY from 275.06 million CNY at the beginning of the year[32] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥200,918,377.93, down 7.10% compared to the previous year[7] - The cash flow from operating activities net amount is ¥200,918,377.93, a decrease from ¥216,285,018.38 in the previous period[49] - The company experienced a net decrease in cash and cash equivalents of ¥659,463,322.36, contrasting with an increase of ¥73,708,871.42 in the previous period[52] - The ending balance of cash and cash equivalents stood at ¥620,788,270.41, down from ¥1,280,251,592.77 at the beginning of the period[52] - Cash inflow from financing activities totaled ¥850,508,517.98, an increase from ¥579,350,000.00 in the prior period[52] - The net cash flow from financing activities was ¥91,993,022.46, a significant improvement from a net outflow of ¥92,423,177.27 previously[52] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,383, with the top 10 shareholders holding a combined 70.27% of shares[16] - Li Shoujun, a domestic individual, holds 35.78% of shares, amounting to 167,474,479 shares, with 36,100,000 shares pledged[16] - The total number of restricted shares at the beginning of the period was 142,299,928, with 126,575 shares released and 2,813,039 shares added, resulting in 144,986,392 restricted shares at the end of the period[22] - The company completed the cancellation of 43,401 shares from its repurchase account and 70,575 shares from the 2019 restricted stock incentive plan, reducing total shares from 468,132,762 to 468,018,786[24] Investments and Subsidiaries - The company reported a significant increase in trading financial assets, which rose by 113.88% to ¥1,235,994,616.46[13] - Short-term borrowings increased by 40.81% to ¥832,356,433.28, attributed to new loans taken during the period[13] - Investment income dropped by 88.74% to ¥1,598,199.46, primarily due to the disposal of equity in a subsidiary[15] - The company’s subsidiary, Repu (Tianjin) Biopharmaceutical Co., Ltd., obtained two new veterinary drug registration certificates during the reporting period[26] - The company obtained the approval for the new veterinary drug "Duck Tembusu Virus Live Vaccine (FX2010-180P strain)" and has commenced production and sales[27] - The company increased its stake in its subsidiary Hubei Longxiang Pharmaceutical Technology Co., Ltd. by acquiring 1,697,724 shares, representing 1.3849% of Longxiang's total share capital, at an average price of 2.58 CNY per share, totaling approximately 4.38 million CNY[28] Research and Development - The company is actively advancing the production of "Liver and Gallbladder Oral Liquid," a new veterinary drug aimed at treating infectious bronchitis and mycoplasma infections in chickens[27] - The research and development expenses decreased to ¥74,433,917.50 from ¥85,769,408.06 in the previous period, indicating a reduction of approximately 13%[49] Tax and Expenses - The company’s tax expenses for the current period are ¥28,917,651.33, down from ¥38,847,027.97 in the previous period[49] - The total operating costs for the current period are ¥1,215,102,335.32, an increase from ¥1,167,310,849.13 in the previous period[49]